How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry

被引:4
作者
Bhaskarabhatla, Ajay [1 ]
Anurag, Priyatam [2 ]
Chatterjee, Chirantan [3 ]
Pennings, Enrico [1 ]
机构
[1] Erasmus Univ, Erasmus Sch Econ, NL-3000 DR Rotterdam, Netherlands
[2] Indian Inst Management Lucknow, Lucknow 226013, Uttar Pradesh, India
[3] Indian Inst Management Ahmedabad, Ahmadabad 380015, Gujarat, India
关键词
strategic repositioning; organizational economics; competitive strategy; NATURAL EXPERIMENT; MARKET-STRUCTURE; PRICE CEILINGS; COMPETITION; EVOLUTION; DYNAMICS; SALES; COSTS; ENTRY; DIVERSIFICATION;
D O I
10.1287/stsc.2020.0121
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
We study coercive institutional pressures as an impetus for firms to reposition across intraindustry boundaries. Integrating the literatures on strategic repositioning and submarkets, we predict that firms respond to regulations limiting the profitability of a submarket by repositioning and shifting demand to proximate, unregulated submarkets within the industry. We expect repositioning to be more pronounced for firms with greater ability to shift demand across submarkets. Evidence from pharmaceutical firms' responses to partial price regulation in India supports our hypotheses. Repositioning firms increase prices and sales in the unregulated submarket, consistent with a Dorfman-Steiner-type model of endogenous and costly demand shifting toward the unregulated submarket. We contribute to the literature on strategic repositioning and highlight challenges of regulating industries with internal boundaries and insulated niches.
引用
收藏
页码:209 / 227
页数:19
相关论文
共 90 条
[11]   Regulation, competition, and liberalization [J].
Armstrong, Mark ;
Sappington, David E. A. .
JOURNAL OF ECONOMIC LITERATURE, 2006, 44 (02) :325-366
[12]  
AUBERT C, 2006, REV ECON DES, V10, P113
[13]   PARTIAL-INDUSTRY REGULATION - A MONOPSONY STANDARD FOR CONSUMER-PROTECTION [J].
AYRES, I ;
BRAITHWAITE, J .
CALIFORNIA LAW REVIEW, 1992, 80 (01) :13-53
[14]  
Azoulay P, 2002, J ECON MANAGE STRAT, V11, P551, DOI 10.1162/105864002320757262
[15]  
BAL A, 1986, ECON POLIT WEEKLY, V21, P1029
[16]  
Bar-Nahum Z, 2018, 290055 HEBR U JER DE
[17]   REGULATING A MONOPOLIST WITH UNKNOWN COSTS [J].
BARON, DP ;
MYERSON, RB .
ECONOMETRICA, 1982, 50 (04) :911-930
[18]   Falsified or Substandard? Assessing Price and Non-price Signals of Drug Quality [J].
Bate, Roger ;
Jin, Ginger Zhe ;
Mathur, Aparna .
JOURNAL OF ECONOMICS & MANAGEMENT STRATEGY, 2015, 24 (04) :687-711
[19]   The Song Remains the Same? Technological Change and Positioning in the Recorded Music Industry [J].
Benner, Mary J. ;
Waldfogel, Joel .
STRATEGY SCIENCE, 2016, 1 (03) :129-147
[20]   The Market for High-Quality Medicine: Retail Chain Entry and Drug Quality in India [J].
Bennett, Daniel ;
Yin, Wesley .
REVIEW OF ECONOMICS AND STATISTICS, 2019, 101 (01) :76-90